2-butyrylaminobenzamide | 59525-14-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-butyrylaminobenzamide
• 英文别名: 2-(Butanoylamino)benzamide
• CAS: 59525-14-3
• 化学式: C₁₁H₁₄N₂O₂
• mdl: MFCD00828585
• 分子量: 206.244
• InChiKey: QJFWQGGTNDNSPI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.272
• 拓扑面积：
  72.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-butyrylaminobenzamide 在 劳森试剂 、 sodium hydroxide 作用下， 以 甲苯 为溶剂， 生成 2-propyl-3H-quinazoline-4-thione
  参考文献：
  名称：

  Phosphodiesterase inhibitory properties of losartan. design and synthesis of new lead compounds

  摘要：

  A 4-centre PDE 4 pharmacophore search has been carried out in several 3D-databases containing compounds belonging to different therapeutic areas. Losartan, an angiotensin-II antagonist, has been identified as a new lead compound for developping PDE 4 inhibitors. New families of compounds derived from losartan has been synthesized and their PDE inhibition has been measured. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00058-4
• 作为产物：
  描述：

  2-(丁基氨基)苯甲酸 在 ammonium hydroxide 作用下， 生成 2-butyrylaminobenzamide
  参考文献：
  名称：

  Phosphodiesterase inhibitory properties of losartan. design and synthesis of new lead compounds

  摘要：

  A 4-centre PDE 4 pharmacophore search has been carried out in several 3D-databases containing compounds belonging to different therapeutic areas. Losartan, an angiotensin-II antagonist, has been identified as a new lead compound for developping PDE 4 inhibitors. New families of compounds derived from losartan has been synthesized and their PDE inhibition has been measured. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00058-4

文献信息

• 2-丙基-4-氯喹唑啉衍生物及其制备方法和应用
  申请人：陈春麟

  公开号：CN103910688B

  公开（公告）日：2016-05-25

  本发明涉及2-丙基-4-氯喹唑啉衍生物及其制备方法和应用，提供一种通式(I)所示结构的化合物，通式(I)如说明书定义。本发明的化合物具有良好的抗肿瘤活性，有望被开发成为治疗肿瘤的靶向药物。
• Sarfraz, Muhammad; Sultana, Nargis; Jamil, Muhammad, Revue Roumaine de Chimie, 2018, vol. 63, # 3, p. 227 - 234
  作者：Sarfraz, Muhammad、Sultana, Nargis、Jamil, Muhammad、Tariq, Muhammad Ilyas

  DOI：——

  日期：——
• DOLGOVA, N. A.;LITVYAK, I. G.;SLAVINSKAYA, R. A.;SUMAROKOVA, T. N., IZV. AN KAZSSR. CEP. XIM.,(1989) N, S. 26-33
  作者：DOLGOVA, N. A.、LITVYAK, I. G.、SLAVINSKAYA, R. A.、SUMAROKOVA, T. N.

  DOI：——

  日期：——
• Phosphodiesterase inhibitory properties of losartan. design and synthesis of new lead compounds
  作者：Victor Segarra、M. Isabel Crespo、Ferran Pujol、Jorge Beleta、Teresa Doménech、Montserrat Miralpeix、Jose M. Palacios、Ana Castro、Ana Martinez

  DOI：10.1016/s0960-894x(98)00058-4

  日期：1998.3

  A 4-centre PDE 4 pharmacophore search has been carried out in several 3D-databases containing compounds belonging to different therapeutic areas. Losartan, an angiotensin-II antagonist, has been identified as a new lead compound for developping PDE 4 inhibitors. New families of compounds derived from losartan has been synthesized and their PDE inhibition has been measured. (C) 1998 Elsevier Science Ltd. All rights reserved.